Allakos Inc ALLK:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
113.14quote price arrow up+1.76 (+1.58%)
Volume
288,052
52 week range
41.60 - 157.98

...

Loading . . .

KEY STATS

  • Open109.71
  • Day High114.19
  • Day Low108.09
  • Prev Close113.14
  • 52 Week High157.98
  • 52 Week High Date02/10/21
  • 52 Week Low41.60
  • 52 Week Low Date03/17/20
  • Market Cap6.01B
  • Shares Out53.12M
  • 10 Day Average Volume0.28M
  • Dividend-
  • Dividend Yield-
  • Beta1.01
  • 1 Year % Change70.44

RATIOS/PROFITABILITY

  • EPS (TTM)-3.10
  • P/E (TTM)-36.55
  • Fwd P/E (NTM)-30.67
  • EBITDA (MRQ)-137.962M
  • ROE (MRQ)-28.83%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Allakos Inc News

There is no recent news for this security.

Latest ALLK News From Our Partners

QUOTE FINDER

Profile

MORE
Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the...
Daniel Janney
Non-Executive Chairman
Robert Alexander Ph.D.
Chief Executive Officer
Adam Tomasi Ph.D.
President
Mark Asbury J.D.
General Counsel
Address
975 Island Dr Ste 201
Redwood City, CA
94065-5173
United States